Latest Stock Buy or Sell? Make More Informed Decisions!
Today, The Panic-Proof Portfolio (Stockchase Research) and Robert McWhirter commented about whether BAC-X, IZO-X, RUS-T, LUN-T, TOU-T, EFL-T, LUX-CSE, MBX-T, DOC-X, BUS-X, STC-T, TOU-T, PTQ-X, OTEX-T, VPT-X, CMC-X, KWE-X, SVA-X, ACU-X, WDFC-Q, DOCU-Q, TSN-N, NLOK-Q, WFG-T, MSFT-Q, HLF-N are stocks to buy or sell.
- Page 1/2
- Next Page
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly HLF is a nutritional food company, who is seeing sales benefit from the need to improve diets as the pandemic winds down. Recently reported quarterly sales were up 19% and EPS improved by 71% from year ago levels. Both beat analyst expectations and management again upgraded its guidance. Marketing is focusing on how 28 NFL draft picks have been training with their products. It trades at 19x earnings, compared to peers over 34x. We would buy this with a stop loss at $39, looking to achieve $69 -- upside potential over 39%. Yield 0% (Analysts’ price target is $69.67)
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly MSFT recently reported EPS growth of 45% and revenue growth of 19%. Commercial cloud revenue was up 33%. It trades at 39x earnings, compared to peers over 61x. It pays a smallish dividend, backed by a payout ratio under 40% of cash flow. It is estimated cash reserves grew almost $2 billion and are over $15 billion now. We would buy this with a stop loss of $200, looking to achieve $290 -- upside potential over 20%. Yield 0.90% (Analysts’ price target is $289.71)
computer software
processing
Premium content
TOP PICK
Stockchase Research Editor: Michael O'Reilly With lumber prices up 300% and demand strong for renovations, it is challenging to find an entry into the space at good value. This is the sweet spot for WFG, having 60 facilities in Canada, the US, United Kingdom and Europe. Recently reported sales were up 81%. It trades at 8x earnings, compared to peers over 17x. It pays a small dividend, backed by a payout ratio of under 10% of cashflow. We would buy this with a stop loss at $60, looking to achieve $136 -- upside potential over 38%. Yield 0.82% (Analysts’ price target is $135.70)
west coast forestry
Premium content
PAST TOP PICK
(A Top Pick Nov 26/20, Up 32%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with NLOK has achieved its $24 objective. To remain disciplined, we recommend covering 50% of the position and trailing up the stop to $21. This would all but guarantee a minimum investment return over 23%.
Technology
Premium content
PAST TOP PICK
(A Top Pick Jan 14/21, Up 23.3%)Stockchase Research Editor: Michael O'Reilly Our PAST TOP PICK with TSN has achieved its $80 objective. To remain disciplined, we recommend covering 50% of the position and trailing up the stop to $75. This would all but guarantee a minimum investment return over 19%.
food processing
Premium content
PAST TOP PICK
Premium content
PAST TOP PICK
COMMENT
Stocks at great value? From a technical perspective, some analysts are cautious. US growth stocks have pulled back. Will there be a rebound, or will the correction be 15-20%? Overall, high price earnings growth stocks will have the largest impact. Wednesday's inflation data was higher than expected. Is this transitory, or will it lead to tighter monetary policy? If the outlook continues to be cautious, gold and gold stocks may benefit. This is a correction, though significant, in the secular bull market that started in 2008 and will continue well into 2030.
COMMENT
Interest rates. Rates will have to get to around 3% before it's a headwind to stocks. Inflation will rise, but it won't be a lot higher than expected, as there is too much production capacity and too many supply chain bottlenecks. The question is will there be an equity correction before the end of the year.
BUY
BUY
Credit card sized pouch inserted under the skin into which insulin cells are inserted. Control highs and lows of insulin. Also works with thyroid cells. Distribution platform for many drugs. Very positive. Revolutionary. His 12-month price target is $2.50-3, subject to outcome of trials.
biotechnology
